A trial led Prof Robin Shattock & his colleagues is being developed at Imperial College London. Tests in animals suggest the vaccine is safe and triggers an effective immune response & Experts at Oxford University have already started human trials.
About the vaccine:
The Imperial vaccine is based on a new approach, using synthetic strands of genetic code, called RNA, which mimic the virus. Once injected into the muscle, the RNA self-amplifies – generating copies of itself – and instructs the body’s own cells to make copies of a spike protein found on the outside of the virus. This should train the immune system to recognize and fight coronavirus without having to develop Covid-19.
The unique nature of the Imperial vaccine means that only one volunteer will be immunized on the first day, followed by three more every 48 hours. After a week or so, numbers will slowly ramp up
There are more than 120 coronavirus vaccines in early development across the world. Most of these will never get beyond the laboratory. A further 13 are now in clinical trials: five in China, three in the United States, two in the UK, one in Australia, Germany, and Russia.
Hopes for a successful Covid-19 vaccine have been boosted after 2 leading groups achieved early positive results. The subjects are understood to have shown encouraging levels of neutralizing antibodies, thought to be important in protecting against viral infection & there were no serious side-effects. Another aspect of the immune system, known as T-cells, was mobilized.